BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/9/2026 9:23:53 AM | Browse: 0 | Download: 0
 |
Received |
|
2025-11-28 01:38 |
|
Peer-Review Started |
|
2025-11-28 01:38 |
|
First Decision by Editorial Office Director |
|
2025-12-23 10:03 |
|
Return for Revision |
|
2025-12-23 10:03 |
|
Revised |
|
2026-01-05 14:03 |
|
Publication Fee Transferred |
|
2026-01-09 06:03 |
|
Second Decision by Editor |
|
2026-02-28 02:30 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-02-28 06:21 |
|
Articles in Press |
|
2026-02-28 06:21 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-05-26 08:20 |
|
Publish the Manuscript Online |
|
2026-06-09 09:23 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Efficacy and safety of fruquintinib plus sintilimab in third-line treatment of metastatic colorectal cancer: A single-center experience
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Jun Pan, Ping Li, Yi Zhao, Yu-He Zhou, Ying Zhao, Tian-Long Zhang, Yi-Tian Chen and Xiao-Yuan Chu |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Beijing Bai Qiuen Foundation |
2024-YJ-220-J-010 |
|
| Corresponding Author |
Xiao-Yuan Chu, MD, Department of Oncology, Jinling Hospital, Medical School of Nanjing University, No. 305 Zhongshan East Road, Nanjing 210002, Jiangsu Province, China. chuxiaoyuan0@163.com |
| Key Words |
Metastatic colorectal cancer; Third-line treatment; Fruquintinib; Sintilimab; Immunotherapy; Prognosis |
| Core Tip |
This study evaluated the safety and efficacy of fruquintinib plus sintilimab in third-line treatment of metastatic colorectal cancer (mCRC). One patient achieved complete response, one had stable disease, and four experienced progressive disease. Median progression-free survival was 3.8 months, and median overall survival was 5.7 months. Fruquintinib combined with sintilimab was well tolerated. Common adverse reactions included bone marrow suppression, liver function impairment, and hypothyroidism, predominantly grades 1-2. Fruquintinib combined with sintilimab as a third-line treatment for mCRC appeared effective in patients with microsatellite stable mCRC and a low tumor burden, who experienced a survival benefit. This treatment warrants further exploration. |
| Publish Date |
2026-06-09 09:23 |
| Citation |
Pan J, Li P, Zhao Y, Zhou YH, Zhao Y, Zhang TL, Chen YT, Chu XY. Efficacy and safety of fruquintinib plus sintilimab in third-line treatment of metastatic colorectal cancer: A single-center experience. World J Gastrointest Oncol 2026; 18(6): 117101
|
| URL |
https://www.wjgnet.com/1948-5204/full/v18/i6/117101.htm |
| DOI |
https://doi.org/10.4251/wjgo.v18.i6.117101 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
